Related Experiment Videos
[Transdermal System-Buprenorphine and Fentanyl]
Masui. the Japanese Journal of Anesthesiology
|December 23, 2015
Summary
Transdermal opioids, like fentanyl and buprenorphine patches, offer improved pain management for non-malignant musculoskeletal conditions. Careful monitoring is essential for effective use in Japan
Area of Science:
- Pharmacology
- Pain Management
- Geriatrics
Background:
- Transdermal opioid therapy offers advantages such as prolonged action and reduced impact from oral intake.
- Recent approvals allow transdermal fentanyl and buprenorphine for non-malignant musculoskeletal pain.
- Japan's aging population presents a growing need for effective pain control solutions.
Purpose of the Study:
- To review the pharmacology, efficacy, and adverse effects of the buprenorphine transdermal patch.
- To discuss the clinical application of the fentanyl patch in cancer pain management.
Main Methods:
- Literature review of transdermal opioid pharmacology.
- Analysis of therapeutic efficacy and adverse event profiles.
- Examination of clinical use cases for fentanyl and buprenorphine patches.
Main Results:
- Buprenorphine transdermal patch exhibits specific pharmacokinetic and pharmacodynamic properties.
- Fentanyl patch demonstrates utility in managing cancer-related pain.
- Both agents require diligent patient monitoring and management strategies.
Conclusions:
- Transdermal opioids provide a valuable option for managing non-malignant pain, particularly in aging populations.
- Understanding the specific profiles of buprenorphine and fentanyl patches is crucial for optimal patient outcomes.
- Effective pain management necessitates a comprehensive approach including proper monitoring and administration.